Group 1 - The core point of the article highlights that Southbound funds have reduced their holdings in Sensong International (02155.HK) by 2.4622 million shares on December 30, with a total net reduction of 3.5512 million shares over the last five trading days [1] - Over the past 20 trading days, Southbound funds have reduced their holdings on 16 occasions, resulting in a cumulative net reduction of 11.6012 million shares [1] - As of now, Southbound funds hold 18.7 million shares of Sensong International, accounting for 15.01% of the company's total issued ordinary shares [1] Group 2 - Sensong International Holdings Limited primarily engages in the manufacturing of pressure equipment and provides comprehensive pressure equipment solutions [1] - The company's main products include traditional pressure equipment such as heat exchangers, vessels, reactors, and towers, as well as modular pressure equipment including process modules and skid-mounted units [1] - Additionally, the company offers value-added services such as design, validation, and maintenance of pressure equipment, operating in both domestic and overseas markets [1]

格隆汇12月29日丨森松国际(02155.HK)公告，公司的独立非执行董事菅野真一郎于2025年12月24日离 世。 ...

该信息由智通财经网提供 智通财经APP讯，森松国际(02155)公布，公司的独立非执行董事菅野真一郎先生于2025年12月24日离 世。 ...

森松国际(02155)公布，公司的独立非执行董事菅野真一郎先生于2025年12月24日离世。 ...

Morimatsu International Holdings Company Limited 森松國際控股有限公司 （ 於 香 港 註 冊 成 立 的 有 限 公 司 ） （「本公司 」） （股 份 代 號：2155） 董事名單與其角色及職能 本公司董事（「董事」）會（「董事會」）成員載列如下： 獨立非執行董事： 陳遠秀女士 于建國先生 董事會已設立三個常務董事委員會。下表提供若干董事會成員於該等委員會 所擔任職務的資料： | 董事 | | 董事委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | --- | | 松久晃基先生 | （主席） | | M | M | C | | 陳遠秀女士 | | | C | | M | | 于建國先生 | | | | C | M | 附註： C：相關委員會主席 M：相關委員會成員 2025年12月29日 執行董事： 西松江英先生 平澤準悟先生 湯衛華先生 盛曄先生 川島宏貴先生 非執行董事： 松久晃基先生 （主席） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Morimatsu International Holdings Company Limited 森松國際控股有限公司 （ 於 香 港 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：2155） – 1 – 菅野先生的辭世致使本公司不再符合聯交所證券上市規則（「上市規則」）之規定， 即(i)上市規則第3.10(1)條項下的獨立非執行董事最低人數規定；(ii)上市規則第 3.10A條項下的獨立非執行董事必須佔董事會成員人數至少三分之一的規定；(iii) 上市規則第3.21條及審核委員會職權範圍項下的審核委員會最低成員人數規定 及組成要求的規定；及(iv)上市規則第3.25條及薪酬委員會職權範圍項下的薪 酬委員會組成要求的規定。本公司將合理地盡力適時委任足夠人數的獨立非 執行董事，以符合上市規則的相關規定。本公司將於適當時候刊發進一步公告。 承董事會命 森松國際控股有限公司 行政總裁兼執行董事 西 ...

来源：@证券市场周刊微博 2025年三季度，制药装备相关上市公司业绩大都出现拐点，在此背后是需求端的恢复。随着制药行业复 苏，全球产能进入扩张周期，启动了新一轮产能建设，制药装备行业因此将大为受益。 而据森松国际半年报，2025年上半年其收入26.87亿元，同比下降22.7%；归母净利润3.4亿元，同比下 降10.1%。虽然营收和净利润均同比下滑，但森松国际在手订单却创出历史新高，主要是医药带动新签 订单超预期。上半年，森松国际新签订单59.96亿元，同比增长89.5%。其中，医药新签订单43.72亿 元，同比增长642%。截至2025年6月底，公司在手订单为105.66亿元，同比增长20.4%，创历史新高。 上半年新签订单中，海外订单占比达到92.8%，同比有较大提升。 在此背后是制药装备行业的恢复。随着制药行业复苏，全球产能进入扩张周期，制药装备行业大为受 益。 薛宇/文 2025年以来，在创新药行情催化下，医药行业股价整体表现较好。 其中，年初以来，港股上市公司森松国际（02155.HK）股价由4.303港元/股上涨至最高的11.68港元/ 股，涨幅接近两倍。深挖背后的原因，一方面源自行业恢复，公司订单 ...

Group 1 - The core point of the news is that Southbound funds have reduced their holdings in Sensong International (02155.HK) by 218,000 shares on December 22, 2025, marking a trend of net reductions over recent trading days [1] - Over the past five trading days, Southbound funds have reduced their holdings for four days, with a total net reduction of 326,000 shares [1] - In the last twenty trading days, there have been fifteen days of reductions, totaling a net decrease of 9.319 million shares [1] Group 2 - As of now, Southbound funds hold 190 million shares of Sensong International, which represents 15.28% of the company's total issued ordinary shares [1] - The company specializes in the manufacturing of pressure equipment and provides comprehensive pressure equipment solutions, including traditional and modular pressure equipment [2] - Traditional pressure equipment includes heat exchangers, vessels, reactors, and towers, while modular pressure equipment consists of process modules and skids, as well as modular plants [2]

Group 1 - The core viewpoint of the article highlights that SenSong International (02155) has seen a significant stock price increase, rising over 8% and reaching HKD 9.08, with a trading volume of HKD 22.42 million [1] - According to a report from Cinda Securities, the domestic market is expected to return to rationality starting in the second half of 2024, with gross margins gradually recovering to reasonable levels. This recovery is anticipated to be driven by a rebound in innovative drug financing and frequent BD transactions, leading to a revival in the CMO sector, which will gradually impact the pharmaceutical equipment industry and potentially achieve a cyclical reversal [1] - Open Source Securities reports that SenSong International, as a global leader in high-end pressure equipment, will benefit from the recovery of CAPEX in the pharmaceutical industry and the expansion demands from overseas MNCs. The company has seen rapid growth in new orders, with the release of Phase II capacity in Malaysia shortening project cycles. Additionally, the acquisition of Pharmadue and Bioenhance has strengthened its biopharmaceutical capabilities, while the "MVP" digital solutions are driving rapid performance growth [1]

每经AI快讯，森松国际(02155.HK)一度涨超8%，截至发稿涨7.97%，报9.08港元，成交额2242.05万港 元。 每经AI快讯，森松国际(02155.HK)一度涨超8%，截至发稿涨7.97%，报9.08港元，成交额2242.05万港 元。 ...